TriVent Healthcare — Payer Strategy
The Payer Case for Ventilator Liberation
$54,000+ Per Episode: A Payer Strategy for Prolonged Mechanical Ventilation
Economic Analysis & Partnership | For Health Plans
How Medicare Advantage, commercial, and Medicaid plans can reduce total cost of care, improve Star Ratings and HEDIS performance, and elevate member experience for one of healthcare’s most expensive patient populations.
Headline Economics
| Cost Category | Standard LTACH Pathway | TriVent VLU Pathway | Payer Δ |
|---|---|---|---|
| LTACH Inpatient Stay | ~$80,000+ | $58,000 | −$22,000 |
| 30-Day Readmission Expected Cost | ~$8,750 (35% × $25K) | ~$1,800 (7.2% × $25K) | −$6,950 |
| Post-Acute Placement Cost | ~$15,000 | ~$10,000 | −$5,000 |
| Conservative Per-Episode Savings Subtotal | — | — | ~$33,950 |
| Plus: Avoided Long-Term Vent Dependence | — | — | +$10,000 – $25,000 |
| Realistic Per-Episode Savings Range Total | — | — | $44,000 – $58,000+ |
Figures use published Medicare LTACH per-diem ranges, CMS readmission cost averages, and conservative outlier-day estimates. A plan-specific model can be built using your claims data.
Executive Summary
Prolonged Mechanical Ventilation (PMV) is among the most expensive, lowest-outcome patient populations in any payer’s book of business. The standard care pathway — acute care hospitalization followed by transfer to a long-term acute care hospital (LTACH) produces roughly 50% wean rates and ~40% 90-day mortality, while costing payers $150,000 or more per episode in combined acute, LTACH, post-acute, and readmission spend.
TriVent Healthcare operates dedicated, in-hospital Ventilator Liberation Units (VLUs) that consistently deliver 86%+ liberation rates, sub-8% 30-day readmission rates, and substantially better functional recovery — at a measurable reduction in total cost of care for the responsible payer. This document quantifies the per-episode and aggregate economic impact for a health plan, identifies five distinct partnership models, and outlines a 90-180 day pilot framework for any plan willing to test the model with a defined cohort of members.
The data underlying this analysis is drawn from 1,023 consecutive PMV patients treated at the UAB TriVent VLU between October 2016 and January 2026 — the largest single-site PMV cohort in the United States built on a single, consistent operating model.
For payers, prolonged mechanical ventilation is not a clinical category — it’s a cost center. And it’s been hiding in plain sight.
The Hidden Payer Cost of Prolonged Mechanical Ventilation
PMV patients are among the most resource-intensive members in any covered population. They consume disproportionate ICU and post-acute spend, generate elevated readmission rates that compound over months, and frequently progress to chronic ventilator dependence — a long-tail cost that quietly erodes plan margins for years.
The standard care pathway for these members produces several layers of avoidable payer expense:
- Long-term acute care hospital (LTACH) transfers that pay separately from the acute hospitalization. The average LTACH stay for a vent-dependent patient runs 25-35 days at $2,000-$3,500 per day, generating $60,000-$100,000 in pure post-acute cost — for a wean rate of approximately 50%.
- Persistent readmissions spend. PMV patients carry 30-day all-cause readmission rates of 35-40%. Each readmission averages $20,000-$30,000.
- Post-acute mismatch. Patients who fail to wean often cycle through skilled nursing facilities (SNFs), home health with respiratory support, or chronic ventilator facilities — most of which would have been avoidable with successful liberation upstream.
- Lost IRF eligibility. Patients transferred to LTACH frequently lose eligibility for inpatient rehabilitation facility (IRF) admission. This forfeits a Medicare-covered functional recovery pathway that produces better long-term outcomes at lower cost than chronic vent dependence.
Layered on top of the direct medical cost are the indirect costs that payers feel acutely: poor patient and family experience driving disenrollment, poor mortality and complication outcomes that pull down quality scores, and network adequacy challenges in regions where LTACH capacity is constrained.
The Outcomes Gap
The following table compares the two predominant pathways for a PMV patient — and why payers should care which one their members are routed through.| Outcome Measure | LTACH Pathway | TriVent VLU Pathway | Payer Implication |
|---|---|---|---|
| Ventilator Liberation Rate | ~50% | 86.2% | Reduced chronic vent dependence |
| 30-Day Readmission Rate | 35–40% | 7.3% | Materially lower readmission spend |
| 90-Day Mortality | ~40% | ~4% | Improved quality measures, member retention |
| Mean Unit Length of Stay | 25–35 days | 21.7 days | Faster recovery trajectory |
| Disposition to Lower Care / Home | Low | High | Reduced post-acute spend |
| IRF Eligibility Preserved | No (lost on LTACH transfer) | Yes | Access to better functional recovery pathway |
| Patient / Family Experience | Variable, fragmented | Concentrated, multidisciplinary | Member experience and NPS impact |
The gap is not marginal. It is the difference between a 50% chance and an 86% chance of liberating your member from the ventilator. For a payer’s actuarial team, that delta translates into measurable per-member savings in the same plan year, with downstream effects that compound over 12, 24, and 36 months.
Per-Episode Economic Analysis
The following analysis quantifies the payer impact of routing a single PMV member through a TriVent-operated VLU rather than the standard LTACH pathway. Figures are intentionally conservative.
Direct Medical Cost Differential
| Cost Driver | Notes | Standard Pathway | TriVent VLU Pathway |
|---|---|---|---|
| Acute Care DRG (Host Hospital) | DRG 003/004 base + outliers | ~$85,000 | ~$85,000 |
| LTACH Stay | 28 days × $2,500/day average | ~$80,000 | ~$58,000 |
| Expected 30-Day Readmission | Probability-weighted readmission cost | ~$8,750 | ~$1,800 |
| Post-Acute Placement (SNF/HHA mix) | Skilled nursing, home health, etc. | ~$15,000 | ~$10,000 |
| Direct Cost Subtotal Subtotal | ~$188,750 | ~$154,800 |
Long-Tail Savings (Probability-Weighted)
| Driver | Estimated Per-Episode Value |
|---|---|
| Avoided Chronic Vent Dependence Multi-year cost tail | $10,000 – $25,000 |
| Improved IRF Utilization vs. extended SNF / chronic vent | $3,000 – $8,000 |
| Reduced 60-Day & 90-Day Readmission Costs Beyond 30-day window | $2,000 – $5,000 |
| Long-Tail Subtotal Subtotal | $15,000 – $38,000 |
Realistic total per-episode payer savings: $49,000 – $72,000+.
These figures are conservative. They do not include the actuarial impact of reduced mortality on member retention, the quality score improvements that drive Star Ratings revenue for Medicare Advantage plans, or the network-adequacy benefits of having a differentiated PMV solution in market.
Aggregate Plan Impact
The per-episode economics scale across a payer's PMV population. The following illustrates the annual impact across plans of varying size.| Plan Profile | Annual PMV Members (DRG 003/004) | Conservative Annual Savings | Realistic Annual Savings |
|---|---|---|---|
| Regional MA Plan ~200K lives | ~50 PMV members | $2.45M | $2.45M – $3.6M |
| Mid-Size MA / Commercial Plan ~500K lives | ~125 PMV members | $6.13M | $6.13M – $9M |
| Large MA Plan ~1M lives | ~250 PMV members | $12.25M | $12.25M – $18M |
| National Payer Multi-million lives | ~1,000+ PMV members | $49M+ | $49M – $72M+ |
Member-count assumptions based on published PMV prevalence in commercially insured and Medicare populations. Actual plan-level PMV volume can be calculated using your claims data in approximately 10 business days.
For a Medicare Advantage plan, these savings impact the bid directly through reduced medical cost ratio (MCR), with knock-on benefits to Star Rating-driven rebates and member retention.
Quality, Stars, and HEDIS Implications
Beyond direct cost savings, the TriVent model materially improves measures that payers — particularly Medicare Advantage plans — are evaluated on:
- Plan All-Cause Readmissions (PCR / HEDIS). A 7.3% readmission rate vs. 35-40% benchmark is a top-decile result for this complex population. PCR is a triple-weighted Star measure for MA.
- Mortality and complication rates. Concentrating PMV members in a high-outcome program reduces population-level mortality, with downstream impact on member-experience and clinical-quality measures.
- Members’ Rating of Care / Health Plan. Family caregivers of PMV patients are among the most distressed populations in any plan’s member base. Better care pathway = better experience = lower disenrollment risk.
- Care for Older Adults / functional status preservation. Higher liberation rates and preserved IRF eligibility produce better functional outcomes — a measure increasingly visible in CMS’s emerging quality framework.
For a Medicare Advantage plan, the cumulative impact on Star Rating bid economics may, on its own, justify a network-strategy investment in TriVent-operated VLUs.
The Five Payer Partnership Models
There is no single “right” way for a payer to engage with TriVent. The following five partnership models are arranged from least to most contractually intensive, allowing a plan to start with low-friction engagement and expand over time.
Model 1: Center of Excellence Network Designation
HCA – TriVent-operated VLUs are formally designated as Centers of Excellence within the plan’s network for the PMV episode. The plan’s care management and prior authorization teams direct members to designated COEs. Friction: low. Time to launch: 60-120 days.
Model 2: Prior Authorization Steerage
The plan’s prior authorization criteria for LTACH transfer are revised to require failure on, or unavailability of, an HCA-TriVent-equivalent in-hospital VLU program. Friction: low-medium. Time to launch: 90-180 days. Aligns with the direction many MA plans are already moving on LTACH prior auth.
Model 3: Case Management Referral Program
The plan’s case managers identify members at risk of LTACH transfer and proactively work with attending physicians to route to HCA-TriVent-operated VLUs. Friction: medium. Time to launch: 60-90 days for a defined pilot. Often the easiest entry point for a plan.
Model 4: Direct Value-Based Contract
The plan contracts directly with HCA on a bundled payment, shared savings, or capitated basis for the PMV episode. Risk and savings are shared between plan and TriVent. Friction: high. Time to launch: 6-12 months. Highest economic alignment.
Model 5: Provider Quality Incentive
The plan incorporates use of HCA-TriVent-operated VLUs into pay-for-performance contracts with member hospitals, rewarding hospitals that operate or refer to HCA-TriVent units. Friction: medium. Time to launch: tied to provider contract renewal cycle.
Most plans will start with Model 1 or Model 3 to demonstrate impact, then progress to Model 4 once the savings have been validated against claims data.
Why This Aligns with Where Payers Are Already Going
The TriVent model is not a strategic detour. It is a direct extension of the trends already shaping payer behavior:
- CMS site-neutral payment rules are compressing LTACH reimbursement and reducing the post-acute cost arbitrage that historically masked LTACH inefficiency. Plans that build alternatives now will be ahead of the curve.
- Medicare Advantage plans are already prior-authorizing LTACH transfers at increasing rates, frequently denying coverage for members where in-hospital alternatives exist. TriVent-operated VLUs are exactly that alternative.
- Value-based care contracting is expanding into specialty episodes. PMV is one of the highest-cost, lowest-outcome episodes available for VBC structuring.
- Member experience and NPS are increasingly tied to payer competitiveness. The PMV member’s family is a high-touch, high-emotion experience that today’s standard pathway badly fails.
A plan that operationalizes a TriVent partnership in 2026 is not innovating — it is staying current with where regulatory and economic gravity is already pulling the industry.
Proven at Scale: The UAB Reference
UAB Hospital in Birmingham, Alabama — one of the top three tracheostomy centers in the United States — has operated a TriVent-managed VLU since October 2016. Outcomes across 891 consecutive PMV patients:| Outcome | Result |
|---|---|
| Ventilator Liberation Rate | 86.2% |
| 30-Day All-Cause Readmission | 7.3% |
| Mean VLU Length of Stay | 21.7 days |
| Avoided ICU Days (Annual) | ~3,000 |
| Hospital LOS Reduction (Medicare patients) | −4.3 days |
| Case Mix Index (Unit) | 15.8 |
These outcomes have been consistent across more than three decades of TriVent’s operational experience, dating to 1991. A UAB-specific case study with more detailed methodology is available on request.
A Pilot Framework
For plans new to TriVent, the recommended starting structure is a 90–180 day pilot with a defined member cohort.| Phase | Duration | Activities |
|---|---|---|
| 1. Claims Data Analysis | 2–4 weeks | Joint review of plan PMV claims; baseline cost and outcomes; market and provider mapping |
| 2. Pilot Design | 2–4 weeks | Define cohort criteria, target volume, partnership model, success metrics, governance |
| 3. Pilot Launch | 30 days | Member identification, care management activation, provider engagement |
| 4. Active Pilot | 90–120 days | Member routing, outcomes tracking, weekly operational review |
| 5. Outcomes Review & Scale Decision | 30 days | Joint analysis of cost, quality, and experience outcomes; scale or refine |
Typical pilot cohorts are 25-50 members, sufficient to demonstrate per-member impact within a single quarter of claims data.
The Next Step: A 45-Minute Strategic Briefing
We can prepare a plan-specific Strategic Briefing for your network strategy and medical management leadership. Using your published claims data (or, where available, joint claims analysis), we will model the potential annual financial impact of a TriVent partnership on your specific book of business — by region, by line of business, and by partnership model — and walk through the operational and contractual considerations for each engagement option.
The briefing is 45 minutes. It is prepared at no cost and no obligation.
Appendix: Methodology and Frequently Asked Questions
Methodology
Outcomes data are drawn from a retrospective review of 1,023 consecutive patients discharged from the UAB TriVent Ventilator Liberation Unit between October 2016 and January 2026. Cost figures use published Medicare LTACH per-diem ranges, CMS DRG payment data, peer-reviewed readmission cost averages, and conservative actuarial assumptions. Per-episode and aggregate impact figures are illustrative; plan-specific modeling against your own claims data is recommended for any partnership-level decision.
Frequently Asked Questions
We don’t directly contract with vent weaning programs. Why would we now? Most partnership models do not require a direct contract with TriVent. Center of Excellence designation, prior authorization steerage, and case management referral programs work within existing network and care management structures. Direct contracting is one option of five, not a prerequisite.
How does this affect our existing LTACH network relationships? The TriVent model is additive, not replacement. Some PMV members will continue to require LTACH-level care. The objective is to route appropriate members to the higher-outcome, lower-cost pathway when one is available — which improves overall network performance without disrupting existing LTACH contracts.
What if our network doesn’t include a TriVent-operated hospital today? TriVent partners with hospital systems to develop new VLU programs, including in regions where current network coverage is limited. A regional gap analysis is part of the Strategic Briefing.
How do we measure success? Standard pilot metrics include: per-member medical cost vs. baseline cohort; 30-day, 60-day, and 90-day readmission rates; mortality outcomes; member and family experience; and downstream post-acute utilization. All measurable from existing claims and quality data.
What is the legal/contractual structure? Varies by partnership model. Center of Excellence designation requires only network-level documentation. Direct value-based contracts require a formal arrangement subject to plan legal and compliance review. TriVent operates under standard healthcare services agreements and complies with all applicable fraud-and-abuse and network-adequacy requirements.
TriVent Healthcare | Confidential | triventhealthcare.com